Breaking News Instant updates and real-time market news.

EVH

Evolent Health

$22.90

-0.3 (-1.29%)

, QADA

Qad Inc.

$53.68

-0.022 (-0.04%)

04:55
06/14/18
06/14
04:55
06/14/18
04:55

William Blair to hold a conference

38th Annual Growth Stock Conference will be held in Chicago on June 12-14.

EVH

Evolent Health

$22.90

-0.3 (-1.29%)

QADA

Qad Inc.

$53.68

-0.022 (-0.04%)

RHI

Robert Half

$70.05

0.66 (0.95%)

GOGO

Gogo

$5.13

0.11 (2.19%)

KAI

Kadant

$95.20

-2.75 (-2.81%)

KIDS

OrthoPediatrics

$25.48

-0.405 (-1.56%)

RMD

ResMed

$106.78

-0.14 (-0.13%)

THR

Thermon Group

$23.74

0.26 (1.11%)

NKTR

Nektar

$53.46

-0.12 (-0.22%)

ULTA

Ulta Beauty

$247.55

-0.68 (-0.27%)

ROLL

RBC Bearings

$130.52

1.25 (0.97%)

NVTA

Invitae

$8.11

0.16 (2.01%)

MA

MasterCard

$199.34

-0.7 (-0.35%)

POOL

Pool Corp.

$149.43

-0.92 (-0.61%)

SHOP

Shopify

$164.96

-0.455 (-0.28%)

MITK

Mitek Systems

$8.90

0.15 (1.71%)

LII

Lennox

$208.50

-3.86 (-1.82%)

SITE

SiteOne Landscape

$88.20

-0.98 (-1.10%)

CCOI

Cogent

$52.85

-0.65 (-1.22%)

BL

BlackLine

$48.98

1.47 (3.09%)

LH

LabCorp

$187.71

-1.23 (-0.65%)

TYL

Tyler Technologies

$235.84

-0.715 (-0.30%)

SIX

Six Flags

$71.52

-0.53 (-0.74%)

GRUB

GrubHub

$115.99

3.16 (2.80%)

SMG

Scotts Miracle-Gro

$85.69

-1.135 (-1.31%)

ULTI

Ultimate Software

$271.66

1.2 (0.44%)

FMI

Foundation Medicine

$103.45

2.85 (2.83%)

  • 14

    Jun

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 12

    Jul

EVH Evolent Health
$22.90

-0.3 (-1.29%)

06/07/18
PIPR
06/07/18
NO CHANGE
Target $30
PIPR
Overweight
Evolent Health new Medicaid deals partially de-risk 2019, says Piper Jaffray
Piper Jaffray analyst Sean Wieland notes that Evolent Health announced two additional partnerships in Florida with providers who will take on Medicaid risk. This expands the company's eligible Medicaid membership reach in Florida to 1.1M and should drive $35M-$45M in revenue next year, he contends. The analyst believes these wins de-risk next year, while also driving operating leverage. Additionally, Wieland argues that there is more upside than downside on the risk/reward profile of the new partnerships. The analyst reiterates an Overweight rating and $30 price target on the shares.
06/07/18
RHCO
06/07/18
NO CHANGE
Target $30
RHCO
Buy
Evolent Health price target raised to $30 from $20 at SunTrust
SunTrust analyst Sandy Draper raised his price target for Evolent Health to $30 and reiterated a Buy rating on the shares after the company announced three Florida Medicaid deal wins, bringing the total to four partnerships that will serve five Florida Medicaid regions. In a research note to investors, Draper said he is not changing his estimates after the deals, but they do provide incremental visibility into 2019 estimates, and thinks the size and scope of the deals further illustrates the market need for Evolent's provider-sponsored health plan services and improving pipeline conditions.
06/07/18
CANT
06/07/18
NO CHANGE
Target $28
CANT
Overweight
Evolent Health positioned for strong 2019 growth, says Cantor Fitzgerald
Evolent Health has now announced eight new partnerships this year and is well positioned to post strong growth in 2019, Cantor Fitzgerald analyst Steven Halper tells investors in a research note. He believes Evolent continues to demonstrate solid execution as it continues to add new partnerships. The analyst keeps an Overweight rating on the shares with a $28 price target.
06/04/18
PIPR
06/04/18
INITIATION
Target $30
PIPR
Overweight
Evolent Health initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Sean Wieland started Evolent Health with a Buy rating and $30 price target. The company has proven the ability to drive clinical and financial improvement for its 35 clients, Wieland tells investors in a research note. He believes the company will post strong top-line growth and improving operating leverage.
QADA Qad Inc.
$53.68

-0.022 (-0.04%)

05/11/18
WBLR
05/11/18
NO CHANGE
WBLR
Outperform
Qad Inc. shares remain undervalued, says William Blair
William Blair analyst Bhavan Suri says he left Qad Inc.'s Explore Conference "incrementally more confident" in the company's ability to sustain subscription revenue growth of 30%-plus over the next few years. Increasing acceptance of cloud solutions and an improving manufacturing backdrop create favorable secular trends in the manufacturing industry, Suri tells investors in a research note. He continues to believe shares of Qad remain undervalued and keeps an Outperform rating on the name.
11/22/17
ADAM
11/22/17
NO CHANGE
Target $44
ADAM
Buy
QAD Inc. price target raised to $44 from $36 at Canaccord
Canaccord analyst Richard Davis raised his price target on QAD Inc. to $44 from $36, noting that new and existing customers are adopting the company's more flexible and cost effective version of its ERP system. The analyst, who sees valuation as quite attractive especially for patient investors, reiterated his Buy rating on QAD Inc. shares.
04/05/18
WBLR
04/05/18
NO CHANGE
WBLR
Outperform
Qad shares remain undervalued, says William Blair
William Blair analyst Bhavan Suri continues to think shares of Qad Inc. are undervalued after hosting investor meetings with management. The analyst is "incrementally more confident" in the company's ability to sustain 25%-plus subscription revenue growth over next few years driven by continued net new customer wins as well as conversions to its cloud offering from existing on-premises customers. Suri also expects continued improvement in EBITDA margins, which he believes could reach 15% in the medium term. The analyst maintains an Outperform rating on Qad Inc.
11/22/17
STFL
11/22/17
NO CHANGE
Target $45
STFL
Buy
QAD Inc. price target raised to $45 from $40 at Stifel
Stifel analyst Brad R. Reback raised his price target on QAD Inc. to $45 from $40 after the company reported "another solid quarter," stating that he believes the company is making solid progress on its transition to a subscription-based model. He maintains a Buy rating on the stock.
RHI Robert Half
$70.05

0.66 (0.95%)

04/09/18
NOMU
04/09/18
NO CHANGE
Target $70
NOMU
Buy
Robert Half price target raised to $70 from $67 at Nomura Instinet
Nomura Instinet analyst Dan Dolev raised his price target for Robert Half to $70 saying his firm's predictive model of companies' capital spending versus Robert Half's temp organic growth points to "yet another positive inflection" in Q1. The algorithm predicts the acceleration in spend spend across multiple end-markets could drive 5%-plus organic temp growth in Q1, Dolev tells investors in a research note. He raised his estimates for Robert Half and reiterates a Buy rating on the shares.
04/03/18
LEHM
04/03/18
UPGRADE
Target $66
LEHM
Overweight
Robert Half upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Manav Patnaik upgraded Robert Half (RHI) to Overweight and raised his price target for the shares to $66 from $62. The analyst views the company's positioning in the U.S. as strong and he favors the shares to Manpower (MAN), which he downgraded this morning to Underweight. He believes Robert Half will benefit from the current all-time high levels of small business confidence.
04/03/18
04/03/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. U.S. Steel (X) upgraded to Buy from Neutral at Citi with analyst Alexander Hacking saying he sees "good value" at 10% free cash flow yield in 2018-2019 and "considerably higher" in 2020 and beyond. 2. Schlumberger (SLB) upgraded to Buy from Hold at SunTrust with analyst Ken Sill saying that the company is typically "one of the best stocks to own in down markets" to maintain exposure to oil field services based on its diversification in product and geography. 3. Baker Hughes (BHGE) upgraded to Overweight from Neutral at Piper Jaffray with analyst Bill Herbert citing relative valuation, balance sheet strength and the company's capital light business model for the upgrade. 4. Robert Half (RHI) upgraded to Overweight from Equal Weight at Barclays with analyst Manav Patnaik saying he views the company's positioning in the U.S. as strong and he favors the shares to Manpower (MAN), which he downgraded this morning to Underweight. 5. Cognex (CGNX) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster saying he believes the current valuation is justified by growth expectations for fiscal 2018 and recommends those short take profits following the recent pullback. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/18
GSCO
03/27/18
INITIATION
Target $63
GSCO
Neutral
Robert Half initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst George Tong started Robert Half with a Neutral rating and $63 price target. The analyst rolled out coverage on the Americas Business Services sector with an Attractive rating.
GOGO Gogo
$5.13

0.11 (2.19%)

05/30/18
MSCO
05/30/18
NO CHANGE
Target $3
MSCO
Underweight
Gogo price target lowered to $3 from $7 at Morgan Stanley
Morgan Stanley analyst Simon Flannery said Gogo's recent weak results raise questions about its underlying business, financial model and ability to generate positive free cash flow. Given his expectations for significantly lower commercial aviation North America revenue and profitability, Flannery cut his 2018 adjusted EBITDA estimate for Gogo by about 55% and his 2019/2020 estimates by about 15%. He lowered his price target on Gogo shares to $3 from $7 and maintains an Underweight rating on the stock.
04/11/18
WBLR
04/11/18
NO CHANGE
WBLR
Google interest ups chances of in-flight Wi-Fi acquisition, says William Blair
"We have seen this movie before" is what William Blair analyst Louie DiPalma says after Bloomberg reported yesterday that Google (GOOG, GOOGL) is in advanced talks to acquire Nokia's in-flight connectivity hardware business. Google joins a long list of technology, telecom, and media providers that have exhibited a strategic interest in in-flight Wi-Fi, "although all have thus far stayed on the perimeter," DiPalma tells investors in a research note. The analyst notes that incumbents Gogo (GOGO), Panasonic (PCRFY), ViaSat (VSAT), Global Eagle Entertainment (ENT), and Inmarsat (IMASY) have invested billions toward satellite capacity and infrastructure. The industry is all about scale and potential new entrants would not have any, DiPalma contends. He believes it would take any new entrant many years to build a network from scratch, obtain regulatory approvals, and procure line-fit partnerships. The analyst thinks Google's interest in in-flight connectivity increases the probability that a tech or telecom company would buy an incumbent in the space. DiPalma has Outperform ratings on ViaSat and Gogo and a Market Perform rating on Global Eagle.
05/21/18
UBSW
05/21/18
DOWNGRADE
Target $7
UBSW
Neutral
Gogo downgraded to Neutral from Buy at UBS
UBS downgraded Gogo to Neutral from Buy and lowered its price target to $7 from $14.
05/18/18
NORL
05/18/18
NO CHANGE
Target $1.5
NORL
Underperform
Gogo price target lowered to $1.50 from $3.50 at Northland
Norhtland analyst Paul Penney believes Gogo's issues remain "far reaching and deep," and as a result, cut estimates to take in account lower business and profitability levels. Penney said Gogo's excessive capex spending levels are not sustainable and expects continued equity erosion, leading the analyst to cut his price target to $1.50 from $3.50 and reiterate an Underperform rating.
KAI Kadant
$95.20

-2.75 (-2.81%)

03/01/18
BRRR
03/01/18
INITIATION
Target $110
BRRR
Outperform
Kadant reinstated with an Outperform at Barrington
Barrington analyst Matthew Gall reinstated his Outperform rating on Kadant with a $110 price target. The analyst views the company's internal and acquisition growth as solid.
10/03/17
SIDC
10/03/17
DOWNGRADE
SIDC
Neutral
Kadant downgraded to Neutral from Buy at Sidoti
KIDS OrthoPediatrics
$25.48

-0.405 (-1.56%)

04/05/18
PIPR
04/05/18
NO CHANGE
Target $24
PIPR
Overweight
OrthoPediatrics pullback brings 'excellent' entry point, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says the recent pullback in shares of OrthoPediatrics provides an "excellent" entry point. The stock is down nearly 33% in the past three months despite beating expectations the first two quarters out of the gate as a public company, O'Brien tells investors in a research note. The analyst is unsure why the shares sold off, noting OrthoPediatrics' fundamentals "are quite good" with the company releasing five products in the past twelve months and has another five scheduled during 2018. He keeps an Overweight rating on the shares with a $24 price target.
11/06/17
11/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CarGurus (CARG) was initiated with a Sector Perform at RBC Capital, a Market Perform at Raymond James and JMP Securities, and a Neutral at Goldman Sachs. 2. OrthoPediatrics (KIDS) was initiated with a Buy at Stifel and BTIG while being initiated with an Overweight at Piper Jaffray. 3. Rimini Street (RMNI) initiated with an Outperform at Cowen. 4. Rigel Pharmaceuticals (RIGL) assumed with a Buy at H.C. Wainwright. 5. Great Elm Capital (GECC) initiated with a Neutral at Janney Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/06/17
STFL
11/06/17
INITIATION
Target $23
STFL
Buy
OrthoPediatrics initiated with a Buy at Stifel
Stifel analyst Rick Wise started OrthoPediatrics Corp. with a Buy rating and $23 price target, stating that it offers the most comprehensive and expanding product portfolio to the "historically neglected" market of pediatric orthopedic implants and instruments. He projects OrthoPediatrics' portfolio will support a high-teens revenue CAGR through 2022.
01/05/18
PIPR
01/05/18
NO CHANGE
Target $24
PIPR
Overweight
Piper says OrthoPediatrics' Q4 pre-announcement shows growth 'clicking along'
Piper Jaffray analyst Matt O'Brien noted that OrthoPediatrics pre-announced Q4 revenue that topped his expectations and the consensus view, which he points to as proof that the company's growth story keeps "clicking along." While acknowledging the company will face tough comps next year, he said he is confident the business will continue to accelerate as the company invests its IPO proceeds. O'Brien reiterates an Overweight rating and $24 price target on OrthoPediatrics shares.
RMD ResMed
$106.78

-0.14 (-0.13%)

04/04/18
04/04/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PTC Therapeutics (PTCT) downgraded to Underweight from Equal Weight at Barclays with analyst Gena Wang saying she sees limited upside to 2018 revenue expectations and believes PTC's growth trajectory is fully priced in at current valuation levels. 2. Cloudera (CLDR) downgraded to Neutral from Overweight at JPMorgan and to Hold from Buy at Deutsche Bank. 3. Domino's Pizza (DPZ) downgraded to Hold from Buy at Deutsche Bank with analyst Brett Levy citing valuation. 4. Virtusa (VRTU) downgraded to Hold from Buy at SunTrust with analyst Frank Atkins saying while Virtusa stock has risen 166% since November of 2016, future upside may be more limited. 5. ResMed (RMD) downgraded to Neutral from Buy at Citi with analyst Victor Windeyer citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, Reference Link
04/23/18
UBSW
04/23/18
DOWNGRADE
UBSW
Neutral
ResMed downgraded to Neutral from Buy at UBS
05/30/18
PIPR
05/30/18
NO CHANGE
Target $190
PIPR
Overweight
Inogen recent pullback a buying opportunity, says Piper Jaffray
Piper Jaffray analyst JP McKim views the recent pullback in shares of Inogen (INGN) as unwarranted and recommends buying the shares at current levels. The analyst says his firm's survey of 66 home medical equipment providers indicates the shift to portable oxygen concentrators "remains strong." The market remains in the early innings of this conversion and Inogen is the best way to play this thematic trend, McKim tells investors in a research note. The analyst expects ResMed's (RMD) Mobi to launch this year, but does not expect it to be overly impactful to Inogen. Consensus numbers already reflect a deceleration in growth in the second half of 2018 which is unlikely to materialize, McKim contends. He keeps an Overweight rating on Inogen with a $190 price target.
05/31/18
05/31/18
NO CHANGE

Arcturus Therapeutics reinstates founder Joseph Payne as CEO
Arcturus Therapeutics (ARCT) has named Dr. Peter Farrell as Chairman of the Board of Directors of the company. Joseph E. Payne has been reinstated as President and CEO and Dr. Pad Chivukula has been reinstated as Chief Scientific Officer and COO. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (RMD).
THR Thermon Group
$23.74

0.26 (1.11%)

05/29/18
WBLR
05/29/18
NO CHANGE
WBLR
Outperform
Thermon Group can rally 20%-40% in next 12 months, says William Blair
William Blair analyst Brian Drab attributes the 9% pullback in shares of Thermon Group Holdings in the two days following its fiscal Q4 report to the 3%-5% organic revenue growth guidance for fiscal 2019, which was below expectations. This outlook looks "extremely conservative," particularly given the company will enjoy its easiest comparison as a public company in Q1, Drab tells investors in a research note. He expects Thermon to produce "solid" growth throughout fiscal 2019 and keeps an Outperform rating on the shares. The analyst sees the potential for 20%-40% upside in the stock over the next 12 months.
04/26/18
JRCO
04/26/18
UPGRADE
JRCO
Accumulate
Thermon Group upgraded to Accumulate from Hold at Johnson Rice
11/29/17
WBLR
11/29/17
UPGRADE
WBLR
Outperform
Thermon upgraded to Outperform from Market Perform at William Blair
William Blair analyst Brian Drab upgraded Thermon Group to Outperform citing an improving operating environment, benefits from the CCI Thermal Technologies acquisition and low expectations.
04/26/18
JRCO
04/26/18
UPGRADE
Target $29
JRCO
Accumulate
Thermon Group upgraded to Accumulate at Johnson Rice on better bidding backdrop
As reported earlier, Johnson Rice analyst Martin Malloy upgraded Thermon Group to Accumulate from Hold and raised his price target to $29 from $25. Malloy says his recent opportunity to travel with the company management allowed him in infer an "improved greenfield project bidding environment combined with a strengthening MRO/UE market". The analyst adds that Thermon Group's recent acquisition of CCI Thermal Technologies has diversified its revenue stream into the transportation and natural gas fired power plant areas, while also forecasting expected cash flow generation and improving margins in backlog from improving end market demand.
NKTR Nektar
$53.46

-0.12 (-0.22%)

06/11/18
06/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. SemGroup (SEMG) downgraded to Market Perform from Outperform at Wells Fargo with analyst Michael Blum saying he believes its growth trajectory is mostly reflected in valuation. 2. Host Hotels (HST) and Park Hotels (PK) were downgraded to Sell from Neutral at Goldman Sachs, Host Hotels was also downgraded to In Line from Outperform at Evercore ISI. 3. NXP Semiconductors (NXPI) downgraded to Hold from Buy at SunTrust with analyst William Stein saying the current stock price is above fair value and demands "an explicit view" that the Qualcomm (QCOM) bid will receive approval from China regulators. 4. Nektar (NKTR) downgraded to Neutral from Buy at H.C. Wainwright with analyst Debjit Chattopadhyay saying an updated cut of NKTR-214 data presented at an investor conference on June 06, does not assuage fears on the outlook of NKTR-214 in the post ECHO-301, immuno-oncology combination therapy landscape. 5. DDR Corp. (DDR) downgraded to Underperform from In Line at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/04/18
WBLR
06/04/18
NO CHANGE
WBLR
Outperform
William Blair optimism on NKTR-214 remains unchanged
William Blair analyst Andy Hsieh says his long-term optimism on Nektar Therapeutics' NKTR-214 remains unchanged following this weekend's update. Given the recent epacadostat setback, there has been increasing scrutiny around data generated from single-arm uncontrolled studies from both the medical and investment communities, Hsieh tells investors in a research note. The analyst thinks the new data will not quell the bearish views on NKTR-21 and that investor confusion about the Fleming analysis could further add volatility to today's trading session. He believes the true potential of NKTR-214 might not be fully realized until later this year and keeps an Outperform rating on Nektar.
06/05/18
ADAM
06/05/18
NO CHANGE
Target $94
ADAM
Buy
Nektar data suggests it could play pivotal role in cancer, says Canaccord
Canaccord analyst Arlinda Lee said data for Nektar's NKTR-214+Opdivo continues to show promise and she believes it is indicative of having a central role in cancer therapy with its broad mechanism of expanding and activating T-effector cells and efficacy. She reiterated her Buy rating and $94 price target on Nektar shares, which fell nearly 42% to $52.57 yesterday.
06/11/18
HCWC
06/11/18
DOWNGRADE
Target $54
HCWC
Neutral
Nektar downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay downgraded Nektar Therapeutics to Neutral and cut his price target for the shares to $54 from $97. The stock closed Friday up $1.17 to $54.14. An updated cut of NKTR-214 data presented at an investor conference on June 06, does not assuage fears on the outlook of NKTR-214 in the post ECHO-301, immuno-oncology combination therapy landscape, Chattopadhyay tells investors in a research note. This has been "further punctured by the lack of meaningful updates" in non-small-cell lung carcinoma, the primary driver of NKTR-214's valuation in an environment where competition is better positioned, the analyst contends. Chattopadhyay now has a "less than sanguine read of the emerging data" from Nektar.
ULTA Ulta Beauty
$247.55

-0.68 (-0.27%)

06/01/18
FBCO
06/01/18
NO CHANGE
Target $250
FBCO
Outperform
Ulta Beauty price target raised to $250 from $235 at Credit Suisse
Credit Suisse analyst Michael Binetti slightly raised his FY18 estimates for Ulta Beauty after the company reported "solid" Q1 results, but he also noted that Ulta struck a more cautious tone on near-term trends. Binetti raised his price target on Ulta shares to $250 to reflect expanding peer multiples, but also said he sees somewhat elevated near-term stock risk. Still, he keeps an Outperform rating on Ulta Beauty shares.
06/05/18
GSCO
06/05/18
DOWNGRADE
GSCO
Neutral
Ulta Beauty downgraded to Neutral from Buy at Goldman Sachs
06/05/18
06/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler saying shares have recently recovered, but sales momentum continues to moderate following a deceleration for six consecutive quarters in same-store-sales. 2. Take-Two (TTWO) downgraded to Market Perform from Outperform at BMO Capital with analyst Gerrick Johnson saying he is "concerned" expectations for the Red Dead Redemption 2 release could be overly optimistic and sees a risk to earnings from a potential slowdown in Grand Theft Auto and NBA 2K. 3. Loxo Oncology (LOXO) downgraded to Market Perform from Strong Buy at IFS Securities. 4. Dentsply Sirona (XRAY) downgraded to Neutral from Buy at Northcoast. 5. First Solar (FSLR) downgraded to Neutral from Buy at BofA/Merrill with analyst Julien Dumoulin-Smith saying she expects a "steep" drop in 2018 Chinese solar deployments following China's recent 2018 Solar PV Power Generation Notice, with further declines in 2019/2020 possible. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/05/18
06/05/18
DOWNGRADE
Target $272

Neutral
Ulta Beauty downgraded to Neutral on share recovery at Goldman Sachs
As previously reported, Goldman downgraded Ulta Beauty to Neutral from Buy and raised its price target to $272 from $241. Analyst Matthew Fassler said shares have recently recovered, but sales momentum continues to moderate following a deceleration for six consecutive quarters in same-store-sales. Fassler also believes moderating growth in loyalty members per store is a potential indicator of maturation.
ROLL RBC Bearings
$130.52

1.25 (0.97%)

11/29/17
11/29/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) downgraded to Hold after Broadcom bid at Stifel with analyst Kevin Cassidy arguing the risk in the shares is now greater than the potential reward following the company's recent rejection of Broadcom's (AVGO) $70 per share bid. 2. Paccar (PCAR) downgraded to Neutral from Buy at Citi with analyst Timothy Thein saying he no longer sees catalysts in place to warrant a Buy rating. 3. Colgate-Palmolive (CL) downgraded to Sell from Hold at Societe Generale with analyst Iain Simpson saying Colgate's new focus on investing aggressively in both price and A&P is the right move, but believes consensus is underestimating how long it will take to yield positive results and how much it will cost. 4. Chipotle (CMG) downgraded to Market Perform from Outperform at William Blair with analyst Sharon Zackfia citing the announcement that its founder and CEO Steve Ells will step down following the completion of a search to identify a new CEO. While a new leader may accelerate the company's turnaround longer term, today's move likely signals that Chipotle's trends remain under pressure and creates more near-term uncertainty, Zackfia tells investors in a research note. 5. MAA (MAA) downgraded to Market Perform from Outperform at Raymond James with analyst Buck Horne saying a material acceleration of construction in MAA's core submarkets will create near-term headwinds. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/17
DRXL
12/20/17
INITIATION
Target $140
DRXL
Buy
RBC Bearings initiated with a Buy at Drexel Hamilton
Drexel Hamilton started RBC Bearings with a Buy rating and $140 price target.
11/29/17
11/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Crown Holdings (CCK) initiated with a Neutral at UBS. 2. Viper Energy (VNOM) initiated with a Buy at SunTrust. 3. RBC Bearings (ROLL) initiated with a Buy at CL King. 4. ACM Research (ACMR) initiated with a Buy at Roth Capital. 5. Invitation Homes (INVH) resumed with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/17
KING
11/28/17
INITIATION
Target $142
KING
Buy
RBC Bearings initiated with a Buy at CL King
CL King initiated RBC Bearings with a Buy rating and $142 price target, citing the company's accelerating revenue growth, expanding operating margins and rising book-to-bill ratio.
NVTA Invitae
$8.11

0.16 (2.01%)

08/02/17
AGIS
08/02/17
NO CHANGE
Target $8.33
AGIS
Buy
CombiMatrix deal confusion presents arbitrage opportunity, says Aegis
Aegis analyst Benjamin Haynor noted that SEC filings related to the agreement for CombiMatrix (CBMX) to be acquired by Invitae (NVTA) present two formulas for the calculation of the exchange ratio, which he believes is causing some confusion, creating an arbitrage opportunity. He reiterates his Buy rating on CombiMatrix and raised his price target on the stock to $8.33 from $8.10, adding that the post-announcement rise in Invitae shares may make his target conservative if that move up holds.
01/05/18
LTCO
01/05/18
INITIATION
Target $15
LTCO
Buy
Invitae initiated with a Buy at Ladenburg
Ladenburg initiated Invitae with a Buy and $15 price target.
08/04/17
LTCO
08/04/17
DOWNGRADE
LTCO
Neutral
CombiMatrix downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin Degeeter downgraded CombiMatrix (CBMX) to Neutral citing the takeover by Invitae (NVTA).
MA MasterCard
$199.34

-0.7 (-0.35%)

05/18/18
05/18/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MasterCard (MA) initiated with a Neutral at UBS. 2. AMD (AMD) initiated with an Outperform at Cowen while Intel (INTC) was initiated with a Market Perform. 3. Synthetic Biologics (SYN) initiated with a Buy at H.C. Wainwright. 4. Amneal Pharmaceuticals (AMRX) initiated with a Neutral at JPMorgan. 5. Apollo Commercial (ARI) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/25/18
WEDB
05/25/18
NO CHANGE
Target $90
WEDB
Outperform
PayPal's Outperform rating backed at Wedbush following 'upbeat' investor day
Wedbush analyst Moshe Katri backed an Outperform rating and $90 price target on PayPal (PYPL) following the company's "upbeat" investor day on Thursday, where management discussed monetization strategies for merchants and consumer facing segments, updated medium-term guidance and provided data on non-eBay (EBAY)-related partnerships. The analyst sees a "host" of growth/scale catalysts, including "explosive" transaction growth int he mobile payments space and the ability to monetize its P2P engine Venmo, and believes that over time, given its recent agreements with Visa (V) and MasterCard (MA), PayPal will be able to scale and expand margins.
05/18/18
WEDB
05/18/18
NO CHANGE
Target $90
WEDB
Outperform
iZettle deal to help advance PayPal's international business, says Wedbush
Wedbush analyst Moshe Katri maintained an Outperform rating and $90 price target on PayPal (PYPL) after the company announced its intent to acquire Sweden-based iZettle, which he says will likely advance PayPal's merchant-facing monetization effort by multiple years, while also helping the company's surging international business. In a research note to investors, Katri said he believes next week's investor day on May 24 will provide additional details on the ongoing eBay (EBAY) separation, as well as its capital allocation plan. Over time, Katri believes that given the recent agreements with Visa (V) and MasterCard (MA), PayPal will be able to scale and expand margins.
06/08/18
WEDB
06/08/18
NO CHANGE
Target $100
WEDB
Outperform
PayPal added to Best Ideas List at Wedbush at Wedbush
Wedbush analyst Moshe Katri added PayPal (PYPL) to the firm's Best Ideas List, citing a view that monetization efforts on both consumer and merchant-facing platforms, its partnerships with banks and Visa (V) and MasterCard (MA) and its post eBay (EBAY) separation opportunities could accelerate top-line growth and expand margins. Katri has an Outperform rating on PayPal and raised his price target on the shares to $100 from $90.
POOL Pool Corp.
$149.43

-0.92 (-0.61%)

09/15/17
BARD
09/15/17
NO CHANGE
Target $125
BARD
Outperform
Pool Corp. weakness a buying opportunity, says Baird
Baird analyst David Manthey said he came away confident following the Pool Corp. investor day. He cited the company's growth trajectory, attractive risk/reward, and relative valuation. He would use the recent weakness as a buying opportunity. Manthey reiterated his Outperform rating and $125 price target on Pool Corp. shares.
09/05/17
WBLR
09/05/17
NO CHANGE
WBLR
Outperform
Pool pullback on Amazon fears a buying opportunity, says William Blair
William Blair analyst Ryan Merkel views the recent pullback in shares of Pool Corp. (POOL) on potential Amazon (AMZN) competition as a buying opportunity. After checking in with management, Merkel notes the company's e-commerce market share has been stagnant at 5% of industry sales for several years and that Amazon has been selling pool supplies for over 10 years. Consumers visiting pool retail stores to get their water tested by the professional lab has been a big barrier to the e-commerce channel, Merkel tells investors in a research note. He believes Pool Corp.'s 70% of sales to the professional contractor market is not at risk. He recommends buying Pool shares at current levels.
09/15/17
WBLR
09/15/17
NO CHANGE
WBLR
Outperform
Pool Corp. should be bought at current levels, says William Blair
William Blair analyst Ryan Merkel says buying opportunities in Pool Corp. are rare so investors should buy the stock at current levels following the recent pullback. The company's investor day showed its resilience in the face of e-commerce risk, which has recently weighed on the shares, Merkel tells investors in a research note. He keeps an Outperform rating on the name.
09/15/17
SIDC
09/15/17
UPGRADE
Target $131
SIDC
Buy
Pool Corp. upgraded to Buy from Neutral at Sidoti
Sidoti analyst Anthony Lebiedzinski upgraded Pool Corp to Buy and raised its price target to $131 from $119 on valuation, a roll out to 2019 estimates, and strong fee cash flow for buybacks and dividends.
SHOP Shopify
$164.96

-0.455 (-0.28%)

05/11/18
ROTH
05/11/18
NO CHANGE
Target $165
ROTH
Buy
Shopify price target raised to $165 from $152 at Roth Capital
Roth Capital analyst Darren Aftahi raised his price target on Shopify to $165 from $152 following the company's Unite conference, highlighting a number of key new products announced at the event that he thinks should drive continued growth of its story. Aftahi maintains a Buy rating on Shopify shares.
05/21/18
JPMS
05/21/18
NO CHANGE
Target $85.5
JPMS
Neutral
After Magento deal, Adobe may compete with Shopify before Wix, says JPMorgan
JPMorgan analyst Sterling Auty is keeping his Neutral rating and $85.50 price target on Wix.com (WIX). The analyst says Adobe (ADBE) acquisition of Magento may allow it to "come down market" to compete against Shopify (SHOP) "long before any real head-to-head competition with Wix". Shares of Shopify were down on the Adobe announcement, falling about 2.4% afterhours.
05/22/18
MSCO
05/22/18
NO CHANGE
Target $140
MSCO
Equal Weight
Adobe deal for Magento presents new threat to Shopify, says Morgan Stanley
Morgan Stanley analyst Brian Essex Adobe's (ADBE) $1.68B acquisition of Magento "puts more muscle" behind competition to Shopify (SHOP), specifically the latter's Shopify Plus offering. While he believes Shopify remains well positioned in the near-term to continue taking share up-market, Essex sees the Adobe/Magento combination as a new long-term threat for Shopify investors to consider. The analyst maintains an Equal Weight rating and $140 price target on Shopify shares, which are down about 1% to $143.15 in pre-market trading.
05/14/18
NEED
05/14/18
NO CHANGE
Target $98
NEED
Buy
Wix.com price target raised to $98 from $90 at Needham
Needham analyst Kerry Rice raised his price target on Wix.com (WIX) to $98 after its Q1 revenue beat and better than expected Collections performance. The analyst cites the company's progress in the rollout of its products like Wix Answers and continued ramp of Wix Code. Rice keeps his Buy rating on Wix.com, adding that its 9-times enterprise value to sales valuation multiple is also a discount to that of 13-times at its closest comparable peer Shopify (SHOP).
MITK Mitek Systems
$8.90

0.15 (1.71%)

03/09/18
NATL
03/09/18
INITIATION
Target $14
NATL
Buy
Mitek Systems initiated with a Buy at National Securities
National Securities initiated Mitek Systems with a Buy and $14 price target.
LII Lennox
$208.50

-3.86 (-1.82%)

01/23/18
UBSW
01/23/18
INITIATION
Target $230
UBSW
Neutral
Lennox initiated with a Neutral at UBS
UBS analyst Christopher Belfiore initiated Lennox with a Neutral rating and $230 price target.
10/24/17
FBCO
10/24/17
NO CHANGE
Target $180
FBCO
Neutral
Lennox price target raised to $180 from $171 at Credit Suisse
Credit Suisse analyst Julian Mitchell raised his price target for Lennox to $180 from $171 following Q3 earnings. The analyst reiterates a Neutral rating on the shares.
02/15/18
LEHM
02/15/18
INITIATION
Target $233
LEHM
Overweight
Lennox initiated with an Overweight at Barclays
Barclays analyst Julian Mitchell started Lennox International with an Overweight rating and $233 price target. The analyst initiated 24 Multi-Industry companies with a Neutral sector view.
12/14/17
WELS
12/14/17
NO CHANGE
Target $210
WELS
Market Perform
Lennox price target raised to $210 from $193 at Wells Fargo
Wells Fargo analyst Rich Kwas raised his price target for Lennox to $210 from $193 on valuation and given no material surprises at Investor Day. The analyst reiterates a Market Perform rating on the shares.
SITE SiteOne Landscape
$88.20

-0.98 (-1.10%)

01/23/18
UBSW
01/23/18
DOWNGRADE
Target $72
UBSW
Sell
SiteOne Landscape downgraded to Sell on valuation at UBS
UBS analyst Christopher Belfiore last night downgraded SiteOne Landscape Supply to Sell from Neutral while raising his price target for the shares to $72 from $66. While the company's execution has been solid, the stock's valuation "has runs its course for now," Belfiore tells investors in a research note. He sees continued growth for SiteOne, but limited margin expansion ahead.
03/29/18
WBLR
03/29/18
NO CHANGE
WBLR
Outperform
SiteOne bull case represents 36% share upside, says William Blair
After traveling with SiteOne Landscape management, William Blair analyst Ryan Merkel says, "Our confidence in the long-term opportunity increases every time we hear the story." The company is still "very early in its evolution to become a world-class distributor," Merkel tells investors in a research note. He sees see 36% upside in the shares to $100, which is based on a "bull case" EBITDA of $300M in 2020 at 15 times. The analyst keeps an Outperform rating on SiteOne.
02/21/18
RHCO
02/21/18
NO CHANGE
Target $89
RHCO
Buy
SiteOne Landscape price target raised to $89 from $70 at SunTrust
SunTrust analyst Keith Hughes raised his price target on SiteOne Landscape to $89 after the company's Q4 results and FY18 EBITDA outlook. Hughes says that while the $180-$192M view looked light of $189M consensus, it did not include the recently closed Atlantic Irrigation deal, which could add $5M-$6M in EBITDA this year. The analyst keeps his Buy rating on SiteOne Landscape, citing the company's ability to drive EPS growth of over 30% per year while the residential and commercial cycle remains strong.
01/26/18
WBLR
01/26/18
UPGRADE
WBLR
Outperform
SiteOne Landscape upgraded to Outperform from Market Perform at William Blair
William Blair analyst Ryan Merkel upgraded SiteOne Landscape to Outperform saying the company is a long-term earnings compounder that will benefit from acquisitions.
CCOI Cogent
$52.85

-0.65 (-1.22%)

05/29/18
RBCM
05/29/18
DOWNGRADE
RBCM
Sector Perform
Cogent downgraded to Sector Perform from Outperform at RBC Capital
05/04/18
DBAB
05/04/18
DOWNGRADE
Target $51
DBAB
Hold
Cogent downgraded to Hold on valuation at Deutsche Bank
Deutsche Bank analyst Matthew Niknam downgraded Cogent Communications to Hold from Buy while raising his price target for the shares to $51 from $50. The analyst continues to see "several positive attributes to the Cogent story," but he sees limited upside to current valuation levels.
06/11/18
OPCO
06/11/18
NO CHANGE
Target $57
OPCO
Outperform
Cogent price target raised to $57 from $51 at Oppenheimer
Oppenheimer analyst Timothy Horan raised his price target for Cogent to $57 from $51 as he believes the company benefits from better overall IP transit volumes from improved OTT and share gains. The analyst thinks Cogent will see volume growth above 40% this year and 50% next year, which could drive revenue growth above 10% and EBITDA margin expansion above 150 bps per year. Horan reiterates an Outperform rating on the shares.
05/29/18
RBCM
05/29/18
DOWNGRADE
Target $51
RBCM
Sector Perform
Cogent downgraded to Sector Perform at RBC Capital on valuation
As reported earlier, RBC Capital analyst Kenneth Lee downgraded Cogent to Sector Perform from Outperform but raised his price target to $51 from $46. The analyst says the move to the sidelines is warranted by the limited potential return for the stock based on his new pricing model as well as the company trading at a premium on a relative historical basis. Lee adds that there is a "lack of foreseeable catalysts" that may drive estimates higher.
BL BlackLine
$48.98

1.47 (3.09%)

03/12/18
KEYB
03/12/18
NO CHANGE
Target $52
KEYB
Overweight
BlackLine price target raised to $52 from $46 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for BlackLine to $52 saying partners at the company's user group in San Francisco were increasingly bullish about expanding practices around Intercomany Hub driven by new regulatory and global tax changes. The analyst views BlackLine as a "core cloud software company to own" that is just "starting to scratch the surface" of an $18.5B total addressable market. He keeps an Overweight rating on the shares.
03/19/18
RHCO
03/19/18
DOWNGRADE
RHCO
Hold
BlackLine downgraded to Hold from Buy at SunTrust
03/19/18
RHCO
03/19/18
DOWNGRADE
Target $42
RHCO
Hold
BlackLine downgraded to Hold at SunTrust on valuation
As reported earlier, SunTrust analyst Terry Tillman downgraded BlackLine to Hold from Buy with an unchanged price target of $42. Tillman says that while he remains positive on the company's position in cloud-based finance and accounting, the recent gains in the stock price have made the risk-reward less compelling. The analyst adds that he and the Street are modeling a "notable" deceleration in growth in 2018-2019, calling the stock price "fully valued" while awaiting the next pullback opportunity.
04/05/18
JMPS
04/05/18
NO CHANGE
Target $45
JMPS
Outperform
Under Armour may be adopting BlackLine ICH product, says JMP Securities
JMP Securities analyst Patrick Walravens noted that Under Armour (UAA) posted an open position on its careers website that included language that leads him to believe the sports apparel maker may be adopting BlackLine's (BL) Intercompany Hub, or ICH, product. BlackLine previously commented on its Q4 call that it closed "multiple" ICH deals, but did not disclose any company names associated with those deals, noted Walravens, who keeps an Outperform rating and $45 price target on BlackLine shares.
LH LabCorp
$187.71

-1.23 (-0.65%)

06/08/18
WBLR
06/08/18
UPGRADE
WBLR
Outperform
William Blair upgrades Quest Diagnostics to Outperform on secular tailwinds
William Blair analyst Amanda Murphy upgraded Quest Diagnostics (DGX) to Outperform from Market Perform citing the recent UnitedHealthcare (UNH) contract change and positive secular trends for larger labs. The analyst believes both LabCorp (LH) and Quest should benefit from secular tailwinds. We are in the early innings of a cycle of lab market share shift from hospital labs to independent labs, Murphy tells investors in a research note. She finds it hard to argue that the new it is hard to argue that the new UnitedHealthcare contract is not good for Quest.
06/07/18
06/07/18
UPGRADE
Target $210

Overweight
LabCorp upgraded to Overweight at KeyBanc
As previously reported, KeyBanc analyst Donald Hooker upgraded LabCorp (LH) to Overweight from Sector Weight, with a $210 price target. The analyst sees LabCorp and Quest Diagnostics (DGX) benefiting over time from their recent contracts with United Healthcare (UNH) and Aetna (AET). Between LabCorp and Quest Diagnostics, Hooker sees the former as having the more timely valuation.
06/07/18
06/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Darden (DRI) upgraded to Buy from Hold at SunTrust with Jake Bartlett citing his view that its multiple will expand with modest comp sales outperformance beyond fiscal 2018, accelerating unit growth, resumed acquisitions and a higher dividend. 2. Wingstop (WING) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan saying he believes drivers of same store sales growth and margin upside relative to current consensus 2018 and 2019 estimates exist. 3. LabCorp (LH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Donald Hooker saying he sees LabCorp and Quest Diagnostics (DGX) benefiting over time from their recent contracts with United Healthcare (UNH) and Aetna (AET). 4. Carrizo Oil & Gas (CRZO) upgraded to Buy from Hold at Tudor Pickering. 5. Canadian Solar (CSIQ) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster saying risks from China's new solar policy appear priced in the shares at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/07/18
KEYB
06/07/18
UPGRADE
KEYB
Overweight
LabCorp upgraded to Overweight from Sector Weight at KeyBanc
TYL Tyler Technologies
$235.84

-0.715 (-0.30%)

04/19/18
BNCH
04/19/18
NO CHANGE
Target $250
BNCH
Buy
Tyler Technologies price target raised to $250 after Socrata deal at Benchmark
Benchmark analyst Mark Schappel estimates that Tyler Technologies paid between $110M-$130M to acquire Socrata, a provider of analytics software for government agencies with a focus on enabling connected communities. He thinks the deal fits squarely within Tyler's strategy and complements its current offerings and views the transaction favorably. Schappel raised his price target on Tyler shares to $250 from $225 and reiterates a Buy rating on the shares.
04/24/18
NORL
04/24/18
NO CHANGE
Target $240
NORL
Outperform
Tyler Technologies price target raised to $240 from $200 at Northland
Northland analyst Tim Klasell raised his price target for Tyler Technologies to $240 from $200 after attending the opening day of its user conference. The analyst notes that the Socrata acquisition was highlighted at the management meeting, and while small he thinks it will be leveraged across most of Tyler's product line. Klasell reiterates an Outperform rating on the shares.
04/24/18
NEED
04/24/18
NO CHANGE
Target $250
NEED
Buy
Tyler Technologies price target raised to $250 from $235 at Needham
Needham analyst Scott Berg raised his price target on Tyler Technologies to $250 and kept his Buy rating, citing his observations from the company's annual customer conference yesterday. Berg notes that local government spending looks to remain above-average, driving Tyler Technologies' 10% or more organic revenue growth. The analyst also sees Socrata acquisition producing a "home run" once integration is completed in 2-3 years.
04/23/18
DADA
04/23/18
NO CHANGE
Target $200
DADA
Neutral
Tyler Technologies price target raised to $200 from $190 at DA Davidson
DA Davidson analyst Peter Heckmann raised his price target on Tyler Technologies to $200 ahead of the company's Q1 earnings next week which he expects to produce a modest beat. The analyst is also building the acquisition of Socrata announced last week into his model, though he also warns that in the near term the integration will produce some margin pressure. Heckmann keeps his Neutral rating on Tyler Technologies.
SIX Six Flags
$71.52

-0.53 (-0.74%)

10/05/17
10/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mallinckrodt (MNK) downgraded to Hold from Buy at Canaccord with analyst Dewey Steadman saying he sees a lack of near-term catalysts and believes the story will take time to evolve. 2. GrubHub (GRUB) downgraded to Neutral from Buy at Citi with analyst Mark May citing valuation with the shares up 44% year-to-date. 3. Coach (COH) downgraded to Neutral from Overweight at Piper Jaffray with analyst Erinn Murphy saying the stock is likely to enter a "period of digestion" as the company integrates Kate Spade and as investors "grapple with" its new reporting structure. 4. PNC Financial (PNC) downgraded to Equal Weight from Overweight at Stephens with analyst Terry McEvoy saying he views the shares as fairly valued following the stock's outperformance relative to Super Regional bank peers year-to-date. 5. Six Flags (SIX) downgraded to Long-Term Buy from Buy at Hilliard Lyons with analyst Jeffrey Thomison citing recent share appreciation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/18
STFL
02/21/18
NO CHANGE
Target $78
STFL
Buy
Six Flags selloff a buying opportunity, says Stifel
Stifel analyst Steven Wieczynski attributes Six Flags' post-earnings selloff to three factors: management comments on its partner in Dubai being in arrears on payments related to its international licensing arrangement; the fact that Q4 visitation decreased 3% year-over-year; and the absence of buyback activity in the quarter. However, he views the selloff as a buying opportunity as he believes 2018 is shaping up to be another strong operating year and has the sense the company remains active in pursuit of additional international licensing agreements. Wieczynski raised his price target on Six Flags shares to $78 from $72 and keeps a Buy rating on the stock.
04/26/18
RILY
04/26/18
NO CHANGE
Target $80
RILY
Buy
Six Flags target raised to $80 on 'positive' Q1 at B. Riley FBR
B. Riley FBR analyst Barton Crockett raised his price target for Six Flags Entertainment to $80 from $78 citing this week's "positive" Q1 earnings report. The analyst reiterates a Buy rating on the shares.
01/08/18
WEDB
01/08/18
NO CHANGE
Target $76
WEDB
Outperform
Six Flags price target raised to $76 from $67 at Wedbush
Wedbush analyst James Hardiman raised his price target for Six Flags to $76 from $67 based on a 4.2% dividend yield on his estimated 2018 dividend payout of $3.18. Further, the analyst believes that Six Flags should benefit from news flow over the course of 2018. Hardiman reiterates an Outperform rating on the shares.
GRUB GrubHub
$115.99

3.16 (2.80%)

05/30/18
WELS
05/30/18
NO CHANGE
Target $95
WELS
Market Perform
GrubHub price target raised to $95 from $90 at Wells Fargo
Wells Fargo analyst Peter Stabler raised his price target for GrubHub (GRUB) to $95 from $90, noting that the shares have far outperformed the broader market due to continued solid fundamentals, easing competitive fears, and the announcement of the exclusive Yum! Brands (YUM) partnership. The analyst reiterates a Market Perform rating on GrubHub's shares.
05/22/18
MZHO
05/22/18
NO CHANGE
Target $115
MZHO
Buy
GrubHub price target raised to $115 from $105 at Mizuho
Mizuho analyst Jeremy Scott raised his price target for GrubHub to $115 after hosting investor meetings with management. The analyst left encouraged by the company's "clear commitment to building profitable chain partnerships, starting most importantly with Yum." Grubhub's commitment to a sustainable delivery parity model will likely become its largest competitive advantage as the market consolidates, Scott tells investors in a research note. He keeps a Buy rating on the shares.
05/31/18
ADAM
05/31/18
INITIATION
Target $130
ADAM
Buy
GrubHub assumed with a Buy at Canaccord
Canaccord analyst Maria Ripps assumed coverage on GrubHub with a Buy rating. She believes the company will benefit from a large addressable market, low penetration, and strong management team. She likes the company's aggressive and insightful move in the mass market over the past few years and sees strong structural tailwinds pointing to a longer period of growth. Ripps has a $130 price target on GrubHub shares.
05/10/18
SPHN
05/10/18
NO CHANGE
Target $120
SPHN
Overweight
GrubHub deal with Jack in the Box 'one of many to come,' says Stephens
After GrubHub (GRUB) announced a partnership to provide delivery for hundreds of Jack in the Box (JACK) locations, Stephens analyst Will Slabaugh noted that the deal is not exclusive but he believes it will be "one of many to come" for GrubHub with large national chains. He maintains an Overweight rating and $120 price target on GrubHub shares.
SMG Scotts Miracle-Gro
$85.69

-1.135 (-1.31%)

05/15/18
05/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Gap (GPS) upgraded to Outperform from Market Perform at Telsey Advisory. 2. CBS (CBS) upgraded to Outperform from Market Perform at Bernstein with the firm saying it views the probability of a CBS-Viacom (VIAB) re-merger as close to zero, for many years to come. 3. Ulta Beauty (ULTA) upgraded to Outperform from Perform at Oppenheimer with analyst Rupesh Parikh saying he still sees the potential for more gains and outperformance from current levels. 4. Valeant (VRX) upgraded to Buy from Neutral at Mizuho with analyst Irina Koffler saying adjusting individual product growth estimates has made her more constructive on Valeant's turnaround story. 5. Scotts Miracle-Gro (SMG) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying he believes the bottom in the stock price has been reached, leading to its usual "counter seasonal trend of outperformance" given that the stock has outperformed the S&P500 from June to January in the past 11 of 15 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/01/18
JPMS
06/01/18
DOWNGRADE
Target $85
JPMS
Underweight
Scotts Miracle-Gro downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Scotts Miracle-Gro to Underweight and lowered his price target for the shares to $85 from $95.
06/01/18
JPMS
06/01/18
DOWNGRADE
Target $85
JPMS
Underweight
Scotts Miracle-Gro downgraded to Underweight with $85 target at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Scotts Miracle-Gro to Underweight from Neutral and lowered his price target for the shares to $85 from $95. The company faces challenges both in its core consumer business and in its hydroponics operation, which serves the cannabis market, Zekauskas tells investors in a research note. He sees a low probability of the stock trading higher on Scotts' mid-June update at an investor conference. He also believes the probability of "stellar" fiscal Q3 results is low.
06/01/18
06/01/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Southwest (LUV) downgraded to In-Line from Outperform at Imperial Capital with analyst Michael Derchin saying he expects Southwest to face unit revenue pressures through fiscal 2019 from higher capacity growth in the "weaker" off-peak period as well as heightened competition in California and Denver. 2. AbbVie (ABBV) downgraded to Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying the stock's risk/reward, while once compelling on the reward side, may be skewing increasingly toward risk. 3. Scotts Miracle-Gro (SMG) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the company faces challenges both in its core consumer business and in its hydroponics operation, which serves the cannabis market. 4. Owens Corning (OC) downgraded to Hold from Buy at Argus. 5. Perry Ellis (PERY) downgraded to Market Perform from Outperform at IFS Securities and to Neutral from Buy at Sidoti. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ULTI Ultimate Software
$271.66

1.2 (0.44%)

05/02/18
RHCO
05/02/18
NO CHANGE
Target $280
RHCO
Buy
Ultimate Software price target raised to $280 from $250 at SunTrust
SunTrust analyst Terry Tillman raised his price target on Ultimate Software to $280 from $250 and kept his Buy rating after the company's Q1 results, saying the upside in recurring revenues produced better than expected margins and cash flows. The analyst notes that the management's commentary about the pipeline was also positive, supporting his view that the company's guidance for FY18 is on the conservative side.
05/02/18
WEDB
05/02/18
NO CHANGE
Target $260
WEDB
Neutral
Ultimate Software price target raised to $260 from $255 at Wedbush
Wedbush analyst Steve Koenig raised his price target for Ultimate Software to $260 from $255 saying it continues to benefit from a strong demand environment, solid market position, and good execution, as evidenced by Q1 results. The analyst reiterates a Neutral rating on the shares.
05/02/18
FBCO
05/02/18
NO CHANGE
Target $280
FBCO
Outperform
Ultimate Software price target raised to $280 from $255 at Credit Suisse
Credit Suisse analyst Michael Nemeroff raised his price target for Ultimate Software to $280 from $255, citing a clean beat with a CFO transition, new international aspirations, and an eye on M&A. The analyst reiterates an Outperform rating on the shares.
05/02/18
NEED
05/02/18
NO CHANGE
Target $280
NEED
Buy
Ultimate Software price target raised to $280 from $250 at Needham
Needham analyst Scott Berg raised his price target on Ultimate Software to $280, saying the company's Q1 outperformance on revenues was its best in three years. The analyst also expects the company's CFO transition to be seamless, while noting that its push into European markets can be a "significant catalyst" in achieving its $3B revenue target. Berg keeps his Buy rating on Ultimate Software.
FMI Foundation Medicine
$103.45

2.85 (2.83%)

02/15/18
02/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Portland General Electric (POR) initiated with a Buy at Mizuho. 2. Arsanis (ASNS) initiated with an Overweight at Cantor Fitzgerald. 3. Cantor says PolarityTE (COOL) can revolutionize regenerative medicine. 4. Foundation Medicine (FMI) initiated with an Outperform at Cowen. 5. Box (BOX) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/29/18
GSCO
01/29/18
INITIATION
Target $73
GSCO
Neutral
Foundation Medicine initiated with a Neutral at Goldman Sachs
Goldman analyst Patrick Donnelly initiated Foundation Medicine with a Neutral and $73 price target.
02/15/18
COWN
02/15/18
INITIATION
Target $90
COWN
Outperform
Foundation Medicine initiated with an Outperform at Cowen
Cowen analyst Doug Schenkel started Foundation Medicine with an Outperform rating and $90 price target. The company is the "uniquely positioned" leader in comprehensive cancer profiling, Schenkel tells investors in a research note. He believes Foundation's clinical volumes are likely to accelerate following the recent CMS/FDA dual path approval.

TODAY'S FREE FLY STORIES

KNL

Knoll

$17.82

-0.12 (-0.67%)

15:42
12/10/18
12/10
15:42
12/10/18
15:42
Conference/Events
Knoll management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

GD

General Dynamics

$171.30

3.92 (2.34%)

, NOC

Northrop Grumman

$268.83

11.28 (4.38%)

15:39
12/10/18
12/10
15:39
12/10/18
15:39
Hot Stocks
Defense stocks rise as Trump said to commit to $750B budget »

Shares of several defense…

GD

General Dynamics

$171.30

3.92 (2.34%)

NOC

Northrop Grumman

$268.83

11.28 (4.38%)

UTX

United Technologies

$119.03

-0.43 (-0.36%)

BAESY

BAE Systems

$0.00

(0.00%)

RTN

Raytheon

$169.99

4.75 (2.87%)

BA

Boeing

$324.33

1.12 (0.35%)

LMT

Lockheed Martin

$297.38

11.96 (4.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

FPI

Farmland Partners

$5.68

-0.09 (-1.56%)

15:32
12/10/18
12/10
15:32
12/10/18
15:32
Hot Stocks
Breaking Hot Stocks news story on Farmland Partners »

Vanguard reports 10.23%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FHN

First Horizon

$14.47

-0.65 (-4.30%)

15:30
12/10/18
12/10
15:30
12/10/18
15:30
Options
Call spreads in First Horizon as shares set 52-week lows »

Call spreads in First…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAA

Under Armour

$22.43

-1.02 (-4.35%)

, UA

Under Armour

$21.13

-0.94 (-4.26%)

15:29
12/10/18
12/10
15:29
12/10/18
15:29
Periodicals
Two Under Armour executives ousted after review of expenses, WSJ says »

Under Armour executives…

UAA

Under Armour

$22.43

-1.02 (-4.35%)

UA

Under Armour

$21.13

-0.94 (-4.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 14

    Dec

  • 03

    Mar

DXPE

DXP Enterprises

$34.65

-0.48 (-1.37%)

15:28
12/10/18
12/10
15:28
12/10/18
15:28
Conference/Events
DXP Enterprises management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

BAYRY

Bayer

$0.00

(0.00%)

15:22
12/10/18
12/10
15:22
12/10/18
15:22
Periodicals
Bayer CEO says has not had communication with Elliott, Reuters says »

According to a recent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$20.74

-0.56 (-2.63%)

15:20
12/10/18
12/10
15:20
12/10/18
15:20
Options
Put spreads in US Steel as shares slip to 52-week lows »

Put spreads in US Steel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CASY

Casey's General Stores

$119.48

-1.94 (-1.60%)

15:19
12/10/18
12/10
15:19
12/10/18
15:19
Options
Caseys General Stores options imply 9.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/10/18
12/10
15:17
12/10/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/10/18
12/10
15:16
12/10/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTZ

Hertz

$16.18

-0.4 (-2.41%)

15:10
12/10/18
12/10
15:10
12/10/18
15:10
Options
DOOM puts opened in Hertz »

DOOM puts opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEMI

Chembio Diagnostics

$6.35

0.01 (0.16%)

15:05
12/10/18
12/10
15:05
12/10/18
15:05
Hot Stocks
Breaking Hot Stocks news story on Chembio Diagnostics »

Cortina Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPAR

Spartan Motors

$7.31

0.16 (2.24%)

15:05
12/10/18
12/10
15:05
12/10/18
15:05
Hot Stocks
Spartan Motors director James Sharman buys almost 16K shares of company stock »

Spartan Motors director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
12/10/18
12/10
15:05
12/10/18
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

ASNA

Ascena Retail

$2.96

-0.05 (-1.66%)

15:04
12/10/18
12/10
15:04
12/10/18
15:04
Options
Ascena Retail options imply 27.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

WBT

Welbilt

$13.01

0.03 (0.23%)

15:01
12/10/18
12/10
15:01
12/10/18
15:01
Periodicals
Breaking Periodicals news story on Welbilt »

Hedgeye names Welbilt to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTY

Paylocity

$62.89

0.63 (1.01%)

14:59
12/10/18
12/10
14:59
12/10/18
14:59
Conference/Events
Paylocity management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

OMI

Owens & Minor

$7.14

0.18 (2.59%)

14:54
12/10/18
12/10
14:54
12/10/18
14:54
Hot Stocks
Owens & Minor names Joseph S. Pekala chief information officer »

Owens & Minor, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVIA

Covia

$4.81

-0.45 (-8.56%)

14:50
12/10/18
12/10
14:50
12/10/18
14:50
Hot Stocks
Breaking Hot Stocks news story on Covia »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$26.91

0.57 (2.16%)

14:49
12/10/18
12/10
14:49
12/10/18
14:49
Options
Stitch Fix options imply 30.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

AIG

AIG

$37.12

-0.77 (-2.03%)

14:45
12/10/18
12/10
14:45
12/10/18
14:45
Options
AIG call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

GRO

Agria

$0.00

(0.00%)

14:43
12/10/18
12/10
14:43
12/10/18
14:43
Hot Stocks
Agria agrees to pay $3M to settle fraud charges »

The SEC announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVA

Covanta

$15.44

-0.18 (-1.15%)

14:41
12/10/18
12/10
14:41
12/10/18
14:41
Conference/Events
Covanta management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEX

Terex

$28.31

(0.00%)

14:39
12/10/18
12/10
14:39
12/10/18
14:39
Conference/Events
Terex management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.